Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Author: Shitara Kohei  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 787-793

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content